These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 38783482)

  • 1. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
    Lai C; Xu L; Dai S
    Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
    Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
    J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
    BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
    Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
    Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
    J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XPO1-dependent nuclear export as a target for cancer therapy.
    Azizian NG; Li Y
    J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
    Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
    PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy.
    Newell S; van der Watt PJ; Leaner VD
    IUBMB Life; 2024 Jan; 76(1):4-25. PubMed ID: 37623925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
    Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
    Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.
    Parikh K; Cang S; Sekhri A; Liu D
    J Hematol Oncol; 2014 Oct; 7():78. PubMed ID: 25316614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
    Etchin J; Berezovskaya A; Conway AS; Galinsky IA; Stone RM; Baloglu E; Senapedis W; Landesman Y; Kauffman M; Shacham S; Wang JC; Look AT
    Leukemia; 2017 Jan; 31(1):143-150. PubMed ID: 27211268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
    Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
    Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.